COCP Tingkat bathi reged Cocrystal Pharma Corp

Lambang korporat lan logo Cocrystal Pharma Inc (COCP)

The expansion of small-molecule antiviral drugs is driving the growth of Cocrystal Pharma, Inc. (COCP), as confirmed by the gross margin chart. The value of 53.10 characterizes this level of efficiency. Cost optimization is based on outsourcing production to third-party contractors. A lean staff of highly specialized experts, incentivized by stock options, completes this model, minimizing internal personnel risks and operating expenses.

Rentabilitas reged: Cocrystal Pharma (COCP) kanggo 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar Cocrystal Pharma Corp (COCP)

Analisis dhasar perusahaan:Cocrystal, COCP
Barang unggulan Cocrystal

Analyzing Cocrystal Pharma, Inc. (COCP), the gross margin trend reflects the efficiency of managing direct drug production costs. This ratio measures the profit share after deducting the cost of goods sold, allowing for an assessment of the pricing power of influenza and coronavirus treatments, as well as the resilience of a diversified portfolio of antiviral developments amid market volatility.